MedWatch

Analyst on Ambu downgrade: Doesn't change investment case

Sydbank analyst calls the adjustment "discouraging news" for the medtech company, but highlights that the visualization business isn't affected.

Photo: Ambu / PR

Tuesday evening's Ambu downgrade is obviously not good news, having made waves in the share price on Wednesday, but the medtech company's announcement really doesn't change its investment case, at least according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

"On the face of things it seems to be discouraging news from Ambu. Having said that, Ambu is priced on the expectations for its visualization business, and this isn't where the company has been affected by shipment delays," Løntoft Hansen says, highlighting, however, that the challenges in shipping, which cost the company DKK 75m (USD 11.7m) in the fourth quarter, will bleed into the next financial year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs